Skip to content

Evaluation of the Efficacy and Safety of Transcranial Magnetic Stimulation in the Treatment of Postherpetic Neuralgia

Clinical study on the modulation of pain and brain functional connectivity in patients with postherpetic neuralgia by iTBS-transcranial magnetic stimulation

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600117465
Enrollment
Unknown
Registered
2026-01-23
Start date
2026-01-23
Completion date
Unknown
Last updated
2026-02-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Postherpetic neuralgia

Interventions

experimental group:Sequential stimulation of M1 + DLPFC
control group:M1 + vertex sequential stimulation

Sponsors

The FIrst Affiliated Hospital, College of Medicine, Zhejiang University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1.Meets the IASP diagnostic criteria for postherpetic neuralgia, with a disease duration of >=3 months; 2.18 to 75 years old; 3.The average NRS score for daily pain over the past 1 week was greater than 3 points; 4.It can be used in conjunction with clinical assessment, rTMS treatment and electroencephalogram monitoring. 5.Be able to understand the nature and purpose of the research, be willing to participate and be able to comply with the requirements of the research protocol, including undergoing von Frey filament stimulation and brain electrical monitoring;

Exclusion criteria

Exclusion criteria: 1. TMS contraindications (e.g. presence of magnetic objects, implants, metallic fragments or foreign bodies within the body; unhealed acute wounds or surgical incisions; claustrophobia; presence of any type of vascular stents, clips or prior surgical interventions; inability to lie supine due to medical conditions); 2. Individuals with psychiatric disorders, aphasia, or cognitive impairment (HAMD 17-item score >24, HAMA 14-item score >29, MMSE <= 24); 3. Presence of severe cardiopulmonary dysfunction, extreme debility, or inability to sit upright and cooperate with treatment; 4. Other conditions likely to interfere with study outcomes, such as epilepsy or myocardial infarction; 5. Pregnant or breastfeeding women; 6. Currently participating in other clinical trials or receiving treatment with other investigational medicinal products.

Design outcomes

Primary

MeasureTime frame
Change in pain following stimulation therapy (NRS score);

Secondary

MeasureTime frame
Indicators of Neural Plasticity in the Patient's Brain;SF-MPQ;von Frey thresholds;PGIC;

Countries

China

Contacts

Public ContactFeng Zhiying

The FIrst Affiliated Hospital, College of Medicine, Zhejiang University

fzy1972@zju.edu.cn+86 591 88235148

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 7, 2026